© Enteralia Bioscience 2024 | Web design by Genetic Digital Privacy Policy | Cookie Policy
About Us
Our Team has an enviable track record of delivering projects together
The Enteralia team has a proven track record of delivering products to market. The Enteralia Management Team and Board of Directors is a multidisciplinary group of scientists, entrepreneurs, and executives with decades of experience and a history of work based in several previous successful ventures.
Enteralia was formed in 2021, from Nemysis Ltd, an Irish company with staff and operations distributed around the world.
Our therapeutic work focuses on alleviating the negative consequences of nutrient intolerances and sensitivities, specific to the gastrointestinal tract. We use an enzymatic-based approach to address the first step of the pathogenic cascade of gluten-related disorders.
Enteralia is focused on the pharmaceutical development of E40 and can leverage the diversified, independent platform with multi-product capabilities developed at Nemysis to address Celiac Disease
Celiac Disease and Non-Celiac Gluten Sensitivity are two distinct conditions whereby the ingestion of gluten and other components of wheat leads to serious gastrointestinal symptoms and other severe reactions.
We use a proprietary enzyme, E40, to break down the immunogenic fragments that form after the ingestion of gluten. People suffering from Celiac Disease manifest acute symptoms and other severe reactions from these immunogenic fragments.
Our expertise, network, and resourcing give us unparalleled flexibility and agility on project evaluation. We operate at a variety of functional stages of product development: scouting, pre-clinical, clinical, regulatory, and distribution, adding value at different steps of the product development life cycle. Through this we can reduce risk and flexibly operate and optimise our speed to market.